Maravai Lifesciences Holdings, Inc. ( (MRVI) ) has released its Q3 earnings. Here is a breakdown of the information Maravai Lifesciences Holdings, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Maravai LifeSciences Holdings, Inc., based in San Diego, is a global provider of life science reagents and services, primarily serving researchers and biotech innovators in the fields of nucleic acid synthesis and biologics safety testing.
In its third-quarter 2025 earnings report, Maravai LifeSciences reported a revenue of $41.6 million, a net loss of $45.1 million, and an adjusted EBITDA of negative $10.8 million. The company is undergoing organizational restructuring and cost reduction initiatives, which are reportedly on track.
Key financial metrics revealed a significant year-over-year decline in revenue by 39.7%, primarily due to a 52.9% drop in nucleic acid production revenue, attributed to the absence of high-volume CleanCap orders for vaccine programs. Meanwhile, biologics safety testing revenue increased by 7.2%, driven by strength across most product lines. Despite the revenue decline, the company remains optimistic about its future, with expectations of double-digit sequential revenue growth for its TriLink segment in the fourth quarter.
Looking ahead, Maravai LifeSciences projects its full-year 2025 revenue to be approximately $185 million, excluding potential new acquisitions or high-volume CleanCap orders. The company is focused on resetting and refocusing its operations to deliver improved financial results in the upcoming quarters while maintaining its commitment to customer service.